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property likely contributes to both the fulminant nature ofHigh affinity of anti-GBM antibodies from Goodpasture and
this disease and its resistance to therapy, because persistenttransplanted Alport patients to a3(IV)NC1 collagen.
glomerular Ab deposition has the potential to produce continu-Background. Anti-glomerular basement membrane (anti-
GBM) antibody-mediated diseases are characterized by rapidly ous inflammation, despite removal of circulating Abs and ade-
progressive glomerulonephritis (RPGN) that often results in quate immunosuppression.
irreversible loss of renal function and renal failure. Although
many factors contribute to the fulminant nature and treatment
resistance of this disease, we questioned whether high affinity
Spontaneous production and deposition of anti-GBMautoantibody-a3(IV) collagen interactions lead to persistent
antibody deposition, thereby perpetuating inflammation. To antibodies characterize anti-GBM antibody-mediated
address this hypothesis, the binding kinetics of human anti- diseases. The disease spectrum includes patients with
GBM antibodies (Ab) to a3(IV)NC1 were evaluated using an glomerulonephritis and pulmonary hemorrhage [Good-optical biosensor interaction analysis.
pasture syndrome (GS)], rapidly progressive glomerulo-Methods. Polyclonal anti-GBM Abs were purified by
a3(IV)NC1 affinity chromatography from the sera of patients nephritis (RPGN) without clinical evidence of lung
with anti-GBM AB-mediated diseases, including individuals involvement (type I), and isolated pulmonary hemor-
with Goodpasture syndrome (GS), idiopathic RPGN (N 5 7), rhage [1, 2]. The mortality in patients with GS is highand Alport syndrome (AL) following kidney transplantation
(11%), and 40 to 70% of patients with anti-GBM anti-(N 5 4). The affinity-binding characteristics of the autoantibod-
body-mediated nephritis develop end-stage renal diseaseies were determined using a biosensor analysis system, with
immobilized bovine a3(IV)NC1 dimers. [3–6]. Of potential pathogenic relevance, anti-GBM anti-
Results. All of the autoantibody preparations bound to bodies are frequently produced in patients with Alport’s
a3(IV)NC1, whereas none bound to a1(IV)NC1 (control).
syndrome following renal transplantation, and a signifi-Purified, normal serum IgG did not bind to either antigen.
cant fraction of these patients develops crescentic glo-Estimated dissociation constants (Kd) for the purified autoanti-
bodies were 1.39E-04 6 7.30E-05 s-l (GS) and 8.90E-05 6 merulonephritis that results in the loss of graft function
2.80E-05 s-l (AL). Their estimated association constants (Ka) [7, 8].
were 2.67E104 6 1.8E104 (M-ls-l) and 2.76E104 6 1.70E104 In the spontaneous form of the disease, the factors(M-ls-l) for GS and AL patients, respectively. By comparison
leading to autoantibody production are unclear, how-with other Ab interactions, these Abs demonstrated high affin-
ever, exposure of “hidden” basement membrane anti-ity, with relatively high on (binding) rates and slow off (dissoci-
ation) rates. gens and molecular mimicry have been postulated to be
Conclusions. The results suggest that anti-GBM Abs bind involved in disease induction [9]. Nevertheless, it has
rapidly and remain tightly bound to the GBM in vivo. This
been conclusively demonstrated that the NC1 domain
of a3 chain of type IV collagen [a3(IV)NC1] is the major
autoantigenic target [9–12]. Similarly, in patients with1Contributed equally to this work.
Alport syndrome (AL) who develop anti-GBM disease
Key words: basement membrane, glomerulonephritis, end-stage renal following kidney transplantation, most studies find thatdisease, inflammation, NC1 domain, kidney transplantation, optical
biosensor. the autoantibodies are directed at a3(IV)NC1, despite
a lack of expression of a5(IV)NC1 in the native kidneys
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[13]. Presumably novel a3(IV)NC1 epitopes are ex-and in revised form September 29, 1999
Accepted for publication January 20, 2000 pressed in the transplanted kidney. Anti-a5(IV)NC1 an-
tibody serum activity has also been described, althoughÓ 2000 by the International Society of Nephrology
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the pathogenicity of the latter is less certain (Kalluri, bodies were determined by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE). Enzyme-unpublished observations) [14].
A particularly striking feature of these diseases is their linked immunosorbent assays (ELISA) and dot blot
assays were used to confirm anti-a3(IV)NC1 activity ofresistance to therapy. Despite treatment with plasma-
pheresis to remove circulating antibodies, glucocorti- the purified anti-GBM antibodies, using previously de-
scribed methods [18]. As described later in this article,coids to suppress inflammation, and cyclophosphamide
for immunosuppression to reduce autoantibody produc- the recombinant a3(IV)NC1 was used only for antibody
purification and to test for postpurification antibody re-tion and suppress B- and T-cell activity, irreversible renal
failure is common [3, 5, 15, 16]. This is especially evident activity.
in patients with a significant reduction of GFR at the
Production of bovine a1(IV)NC1 andtime treatment is initiated. Of potential clinical rele-
a3(IV)NC1 dimersvance, these therapies are directed at either removing
circulating antibodies, suppressing autoantibody produc- Bovine a1(IV)NC1 and a3(IV)NC1 dimers were iso-
lated from bovine testis, as previously described [19]. Thetion, or reducing ongoing inflammation. They do not,
however, deal with the possibility that glomerular-bound isolated dimers were characterized by type IV collagen
chain-specific antibodies by ELISA and Western blot,antibody may linger within the glomerulus, with the po-
tential for continuous perpetuation of inflammation and and were shown to be pure before use [19]. These bovine
a1(IV)NC1 and a3(IV)NC1 dimers were used in thefibrosis, despite the aforementioned aggressive, thera-
pies to remove circulating autoantibodies and decrease optical biosensor interaction analysis.
their production. In this regard, deposited anti-GBM
Optical biosensor interaction analysisantibodies tightly bound to a3(IV)NC1 within the glo-
merulus could perpetuate inflammation, prolong injury, Surface plasmon resonance (SPR) was used to deter-
mine antibody–antigen interactions in a BIAcore 2000and limit recovery.
To address this possibility, we examined the kinetics instrument (BIAcore AB, Uppsala, Sweden). The princi-
ples by which optical biosensors operate are describedof anti-GBM antibody-a3(IV)NC1 interactions using au-
toantibodies derived from nephritic patients. Analysis in detail elsewhere [20, 21]. Briefly, SPR occurs when
light at an angle equal to or higher than the criticalof binding and dissociation as a function of time indicated
that anti-GBM antibodies bind rapidly and tightly to angle is directed at the base of a prism onto which a
semitransparent gold film is coupled. This results in totala3(IV)NC1. Once bound, they remain complexed, with
slow dissociation rates. Thus, the results suggest that internal reflection (TIR) at which an evanescent field is
formed. The evanescent field couples with an electro-securely bound anti-GBM antibodies linger within the
glomerulus, in vivo, and that their continued presence magnetic surface wave at the gold/liquid interface called
surface plasmon. The plasmon is a propagating electrodemay perpetuate inflammation, despite the removal of
circulating autoantibodies and suppression of autoreac- mode in a metal at a metal/dielectric interface, which is
maximal at the interface and decays exponentially intive B cells. This phenomenon may contribute to the
accelerated and progressive nature of disease in these intensity in a direction perpendicular to the surface
[22, 23].patients.
The SPR angle at which this coupling occurs is sensi-
tive to the refractive index close to the gold film. By
METHODS
linking the gold film with a single chain (non–cross-
Sera linked) carboxymethylated dextran, it is possible to regis-
ter changes in the evanescent field profile resulting fromAlport syndrome and GS sera were obtained from
patients with active nephritis who had circulating anti- the binding of a protein to the dextran layer, where
resonance angle shifts toward higher values as the refrac-GBM antibodies and linear deposits of IgG along the
GBM. Anti-a1 serum was obtained from a patient who tive index of the aqueous solution in the neighborhood
of the gold surface (100 nm) increases [21]. In the BIA-developed anti-a1 autoantibodies in the setting of lung
carcinoma [17]. core, an integrated microfluidic cartridge (IFC) controls
the continuous flow of buffer or injection of sample over
Expression and purification of the recombinant the dextran surfaces [20]. Different chemical coupling
a3(IV)NC1 antigen and purification of sera from GS reactions are used to couple the antigen to the dextran
and AL patients matrix. By using the negative charge of the matrix and
the positive charge of the antigen, below its pI, it isRecombinant a3(IV)NC1 antigen was prepared as
previously described [10, 18]. Briefly, sera from GS and possible to concentrate the antigen in the dextran layer;
a covalent bond is then formed by previously activatingAL patients were purified over a recombinant a3(IV)NC1
affinity column; the concentration and purity of the anti- the surface with N-hydrosuccinimide (NHS), N-ethyl-
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N9-(3-diethyl-aminopropyl)-carbodiimide (EDC), and dR/dt 5 kon[A](Rmax 2 R) 2 koffR
ethanolamine-hydrochloride.
At equilibrium, the amount of complex formed is
The bovine a1(IV)NC1 and a3(IV)NC1 antigens (pu-
equal to the amount of complex dissociated. Under those
rified from bovine testis) were coupled to the sensor
conditions, dR/dt 5 0 so that redistributing
surface (carboxymethyl-dextran, sensor chips CM5; Re-
Req 5 kon[A]Rmax/kon[A] 1 koffRsearch Grade, BIAcore AB, Uppsala, Sweden) at a flow
of 10 mL 1 min21, as previously described [22]. Spare
Based on these equations, plots of dR/dt versus R,
amine-coupling sites were blocked with 1 mol/L ethanol-
ln(dR/dt) versus t will be linear, with negative slope ks 5
amine, pH 8.0, at a surface density of approximately
kon[A] 1 koff. The extrapolated intercept of the linear
1000 RU per sample per surface; however, the maximum portion of the derivative of the binding signal would
autoantibody binding capacity of these surfaces was correspond to the expected signal in RU at steady state.
found to be around 200 RU after repeated immobiliza- The parameters obtained from the linear transforma-
tion assays. The surfactant Tween P-20, phosphate-buf- tions of the raw data were compared with the BIA evalu-
fered saline, NHS, EDC, and ethanolamine-hydrochlo- ation 3.0 estimates of independent analysis of association
ride were obtained from Sigma (St. Louis, MO, USA). and dissociation [24]. Global fit of parameters using the
The purified bovine a1(IV)NC1 and a3(IV)NC1 were two-compartment model to account for the effect of mass
immobilized to a carboxymethylated dextran hydrogel transfer (diffusion limited kinetics) was evaluated using
layer using EDC/NHS chemistry. At a pH of 4.5, the 3.0.1 BIAevaluation software.
interaction between the a3(IV)NC1 and the negatively
charged carboxyl groups was optimal. Approximately
RESULTS1000 RUs were coupled to the sensor matrix. Adequate
coupling of the bovine a3(IV)NC1 and of bovine a1 (as All of the patients’ purified anti-GBM autoantibodies
a negative control) to the cell surface was achieved (data bound to the a3(IV)NC1 coupled to the biosensor sur-
not shown). It was not possible to immobilize recombi- face. Figure 1A shows the binding of anti-a3(IV)NC1
nant a3(IV)NC1 to the carboxymethylated dextran hy- autoantibodies to immobilized antigen. The injection of
drogel layer, as the E. coli expressed protein precipitated antibody to the sensor surface at a flow of 30 mL/min
from solution despite vigorous attempts to solubilize it resulted in a rapid increase in binding (initial part of the
prior to coupling. curve) to the coupled a3(IV)NC1 (seen as increasing
A blank, activated and blocked under the same proto- RUs as a function of time). At the end of the injection,
col without antigen, was used as an additional control. unbound antibody was washed from the a3(IV)NC1 sur-
The three surfaces (blank, a3 antigen, and a1 antigen) face with phosphate-buffered saline (PBS)/Tween. The
were conditioned twice with HCl 20 mmol/L injections dissociation rate, visualized as an almost horizontal line,
at a flow of 30 mL/min for one minute to purge unbound indicates that the antigen–antibody complex formed was
antigen and to test for stability of the baseline and regen- very stable. All of the patient’s anti-GBM antibodies,
eration. Affinity-purified active serum antibodies were including GS and AL, had slow dissociation rates.
then passed over the three flow cells in series using differ- The GS and AL patient’s autoantibodies bound only
ent concentrations (200 to 6.25 nmol/L, twofold dilu- to the a3(IV)NC1 surface. The anti-GBM antibodies did
tions) in this order: activated blank, a3, and a1. The a1 not bind to the a1 cell, proving their selectivity for the
antigen was used as an additional control surface, and a3(IV)NC1. By contrast, the anti-a1 autoantibodies (de-
it was further tested for specificity by exposure to affinity- rived from a patient with lung carcinoma without dis-
purified anti-a1–specific IgG [17]. Normal human serum ease) bound only to the a1(IV)NC1 surface. The normal
IgG was also passed over the three surfaces; however, human IgG did not bind to either surface. Figure 1B
binding by the normal human IgG antibody fraction was shows the binding of the anti-a1 antibodies to the
never detected. a1(IV)NC1-coupled sensor cell. The anti-a1 antibodies
The kinetics of binding are initially evaluated assum- have a rapid dissociation rate, indicating that this reac-
ing the ligand (analyte) is in solution. The analyte, auto- tion is less stable than that of anti-GBM patients with
antibody [A] interacts with the immobilized antigen [B] autoantibodies to a3(IV)NC1 collagen.
(in this case the antigens a3 and a1, to form complex
Kinetic analysis of anti-GBM antibodies[AB]). The net rate of complex formation depends on
the free concentration of A, the Rmax in RU or maximum To further evaluate the kinetic constants of binding of
binding capacity of the surface, B, and the stability of the anti-GBM antibodies, dose–responses were further
the formed complex AB. Kinetics data are evaluated using analyzed. Figures 2A and 3A show the raw data obtained
relationships described previously [24]. For a bimolecu- from varying concentrations of affinity-purified autoanti-
bodies from a single patient (range 6.25 to 200 nmol/L).lar interaction, the signal change with time is given by
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Table 1. Affinity kinetic values for Goodpasture syndrome (GS)
and Alport syndrome (AL) anti-GBM autoantibodies (at a
uniform 50 nmol/L concentration of autoantibody)
Patients Kd (s-1) Ka (M-1 s-1) KD (Kd/Ka)
GS 1.39 E-4 2.67 E14 5.2 nmol/L
N 5 7 67.3 E-5 61.8 E14 64.1 E-9
AL 8.90 E-5 2.76 E14 3.2 nmol/L
N 5 4 62.8E-5 61.7 E14 61.7 E-9
Combined 1.21E-4 2.70 E14 4.5 nmol/L
N 5 11 66.37 E-5 61.67 E14 63.81 E-9
the ln R0/R1 versus time of dissociation is shown by
Figures 2D and 3D.
BIAevaluation software was used to fit the dissocia-
tion curves from concentrations of 50 to 200 nmol/L in
order to calculate the dissociation constants [Kd(s-1)].
Kd values obtained from curves below the 50 nmol/L
concentration show a wide variation and a high standard
error and x2 score. The signal to noise ratios in the more
dilute samples were too low to obtain statistically signifi-
cant results, and therefore, they were not used in the
analysis.
The calculated Kd values from every patient at a con-
centration of 50 nmol/L were very similar (Table 1).
From these data, using the Kd(s-1) and the antibody
concentration from each sample, it was possible to derive
the association constants, Ka (M-1 s-1), and calculate KD
[KD 5 (Kd/Ka)] values. The results are indicated in Table
1. Particularly noteworthy, all of the anti-GBM autoanti-
bodies derived from patients with nephritis have high
affinities. This was evident from the rapid association
rates and low dissociation rates.
Fig. 1. (A) Sensorgram illustrating binding of purified anti-GBM autoan-
DISCUSSIONtibodies (200 nmol/L) to the a3(IV)NC1 surface (1000 RU density) at
a flow of 30 mL/min. Binding is characterized by a rapid association rate To our knowledge, this is the first report of the kinetic
and very slow dissociation rate. (B) Binding of anti-a1(IV)NC1 antibodies
analysis of human pathogenic autoantibodies derivedto immobilized a1(IV)NC1. Note the faster dissociation of the anti-
a1(IV)NC1 antibodies when compared with the stable formation of the from patients with autoimmune disease directed against
anti-GBM-a3(IV)NC1 complex in 1A. their major antigenic target. The results indicate that
spontaneously produced anti-GBM antibodies have a
high affinity for a3(IV)NC1 collagen; these autoantibod-
ies bind rapidly to their target antigen, and they remainSimilar concentration curves were obtained from each
tightly bound, with slow dissociation rates. The high af-patient and used to determine the kinetics of binding
finities observed in our analysis of anti-GBM antibodiesof the autoantibodies for each individual. The kinetic
are comparable to high-affinity antibodies that developparameters for each patient’s autoantibodies binding re-
during a secondary immune response to foreign anti-sponse were then further estimated from calculations of
gen [25].the linear transformations of the Langmuir equation, as
Affinity-purified anti-GBM antibodies are monospe-described in the Methods section. Figures 2B and 3B
cific but not monoclonal, and therefore, some diversityshow a family of linear plots of the first derivative of the
in the binding characteristics of purified anti-GBM anti-binding signal (rate of signal change) versus the response
bodies from a single patient is expected, which explainsat each time point. The secondary plots of the calculated
the slight deviations from the 1:1 interaction model.slopes [kobs (s-1)] plotted versus the concentration of
Since the kinetic data give a linear transformation, theautoantibody samples are linear with slopes equal to the
bivalent model of interaction in which each antibodykinetic on rate constant kon (Figs. 2C and 3C). The
exponential dissociation of autoantibody described by binds two immobilized a3(IV)NC1 molecules cannot de-
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Fig. 2. (A) Dose response sensorgrams showing increased binding of a typical patient’s GBM antibodies to a3(IV)NC1 coupled to the dextran
surface. The time of contact, 200 seconds, and the flow, 30 mL/min, were constant throughout the experiment. (B) Linear transformation of the
association portion of the binding data in which the derivatives of the binding signal are plotted as a function of the signal at each time point (Methods
section), r 2 for the linear fits $ 0.975. (C) Secondary plots of the association data in which the calculated slopes are plotted as a function of concentration
of antibody give straight lines in the Langmuir model of binding at a surface with slope equal to the kon (M-1 s-1). (D) Linear transformation of the
dissociation data from A as plots of ln (R1/R0) versus time. The calculated slopes are a measure of the koff for the interaction. Koff for the highest
binding signal reported was used in the estimate of the dissociation rate constant for each patient.
scribe the observed kinetics of binding. All patients’ sera conclusion that the major fraction of antibodies were of
high affinity. In this regard, a population of antibodiescontained various amounts of high-affinity a3(IV)NC1
autoantibodies, which can be completely removed by our with low and intermediate affinities was not observed
in any serum, as would be expected if some high- andaffinity purification [26]. These high-affinity antibodies
purified from circulation are the same as those deposited intermediate-affinity antibodies were influenced by elu-
tion, further supporting the conclusion that the majorityin the GBM and are associated with disease onset [27].
Affinity purification with a3(IV)NC1 collagen re- of autoantibodies were of high affinity.
The rapid association rate may contribute to themoved all detectable autoantibody activity from anti-
GBM sera, confirming our previous report [26]. There- abrupt clinical presentation often observed in patients
with these autoantibodies; RPGN is a relatively commonfore, antibody activities of all affinities are removed by
the procedure. Nevertheless, elution, per se, may some- presentation. If appropriate epitopes were exposed,
high-affinity circulating autoantibodies passing throughtimes alter antibody activity, leading to a loss of affinity.
Although we cannot absolutely exclude the possibility the glomerulus would, therefore, be expected to bind
rapidly to a3(IV)NC1 collagen. In this regard, the glo-that there was a small population of low-affinity autoanti-
bodies that were completely destroyed during elution merular milieu is a particularly favorable environment,
since the autoantibody concentration rises as filtrationand lost all antibody activity, the results support the
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Fig. 3. (A) Dose response sensorgrams showing increased binding of Alport patient 5’s antibodies to a3(IV)NC1 coupled to the dextran surface.
The time of contact, 200 seconds, and the flow, 30 mL/min, were constant throughout the experiment. (B) Linear transformation of the association
portion of the binding data in which the derivatives of the binding signal are plotted as a function of the signal at each time point (Methods section).
r2 for the linear fits $ 0.975. (C) Secondary plots of the association data in which the calculated slopes are plotted as a function of concentration of
antibody give straight lines in the Langmuir model of binding at a surface with slope equal to the kon (M-1 s-1). (D) Linear transformation of the
dissociation data from A as plots of ln (R1/R0) versus time. The calculated slopes are a measure of the koff for the interaction. Koff for the highest
binding signal reported was used in the estimate of the dissociation rate constant for each patient. Calculated parameters are reported in Table 1.
occurs throughout the glomerular capillary. Rapid accu- of the antibodies to the sensor surface is a paradigm of
the in vivo situation in which dissociation and rebindingmulation of deposited antibodies would then lead to
the efficient recruitment of inflammatory mediators and to the GBM are likely to occur, it is of particular interest
that the sensor cell surface consists of a 100 nmol/L thicksevere inflammation, typical of patients with anti-GBM
diseases. This phenomenon of rapid association may also layer of a3(VI)NC1 coupled to dextran.
Of potential relevance, rapid association/slow dissoci-explain the failure to detect circulating autoantibodies in
some patients with less sensitive assays, such as indirect ation of the autoantibodies to the GBM in vivo may
contribute to both the rapid onset of disease and resis-immunofluorescence, since many of the autoantibodies
may be removed from the circulation after only a brief tance to treatment. Rapid and persistent antibody bind-
ing would favor a fulminant course, often found in pa-encounter with the GBM in vivo.
The slow dissociation rates are also particularly strik- tients with anti-GBM disease. Persistence of deposited
autoantibodies would lower the threshold for autoanti-ing. Although the bivalent binding capacity of intact
IgG may contribute, if this were the only factor, at high body production required for disease expression since
accumulation of deposited antibodies would be expec-concentrations, a faster dissociation rate would have
been detected because of the unavailability of spare sites ted. Furthermore, once sufficient antibodies were bound
to the GBM, their persistence would continue to incitefor second binding. This was not observed. Although it
is not known whether divalent or monovalent binding inflammation despite the removal of circulating immuno-
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globulins. Although disease progression is influenced by to alter the course of this disease in patients with significant
renal dysfunction at the time of diagnosis.multiple factors, including the individual’s local and sys-
temic inflammatory responses and the capacity of conven-
tional therapies to alter them, the continuous proinflam- ACKNOWLEDGMENTS
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